PAR2 Pepducins in Atopic Dermatitis
PAR2 Pepducin-Based Suppression of Inflammation
and Itch in Atopic Dermatitis Models
Barr T., Garzia C., Guha S., Fletcher E., et al. Journal of
Investigative Dermatology. February 2019.
DOI: 10.1016/j.jid.2018.08.019
Targeting PAR2 with Pepducins
Mellisa S. Lee & Ethan A. Lerner. Journal of Investigative Dermatology. August 2018.
Phase 1 and Phase 2 Clinical Trials with a PAR1 Pepducin
PAR2 Pepducins in NASH, Fibrosis & Inflammation
PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference
A M Shearer, Y Wang, E K Fletcher, R Rana, E S Michael, N N, M F Abdelmalek, L Covic, A Kuliopulos Hepatology Dec 2022.
DOI: https://doi.org/10.1002/hep.32589
Targeting Liver Fibrosis with a Cell Penetrating Protease-activated Receptor-2 (PAR2) Pepducin
Shearer A.M., Rana R., Austin, K., et al. J Biol Chem. October 2016.
Interdicting protease-activated receptor 2-driven inflammation with cell-penetrating pepducins
Sevigny L.M., Zhang P., Bohm A., Lazarides K. et al.
Proc Natl Acad Sci USA. May 2011.
PAR2 Pepducins Suppress Pancreatitis
Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis
L Van Doren, Nguyen N, Garzia C, Fletcher EK, Stevenson R, Jaramillo D, Kuliopulos A, Covic L Arterioscler Thromb Vasc Biol. Jan 2021
Pepducin Review
Lipopeptide Pepducins as Therapeutic Agents
Michael, E, Covic L, Kuliopulos A. Methods Mol Biol.
2022 DOI: 10.1007/978-1-0716-1752-6_21.
GPR31 Anti-stroke/thrombotic Pepducin
Pepducins and Cancer
Protease-Activated Receptor 1 as a Therapeutic Target in Breast, Lung and Ovarian Cancer: Pepducin Approach
Covic L & Kuliopulos A. Int. J. Mol Sci.
July 2018. DOI: 10.3390/ijms19082237
PAR1 Pepducin Therapy Targeting Myocardial Necrosis in CAD and ACS Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study
Kuliopulos, A., Gurbel P.A, Rade, J.J. et al.
Atheroscler Thromb Vasc Biol. December 2020
DOI: 10.1161/ATVBAHA.120.315168
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects with Coronary Artery Disease
Gurbel P.A, Bliden K.P., Turner U.S., Gesheff M.G. et al.
Atheroscler Thromb Vasc Biol. January 2016
Michael ES, Kuliopulos A, Covic L, et al. Am J Physiol Gastrointest Liver Physiol. Mar 2013.